BDBM387815 US10294226, Compound A::US10487083, Example A::US11059823, Example A

SMILES Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1

InChI Key InChIKey=OETPUWNRYNOSLM-UHFFFAOYSA-N

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 15 hits for monomerid = 387815   

TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 12.4nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.900nMAssay Description:Substrate (NH2-KGGEEEEYFELVKK-CO2), internal standard peptide (NH2-SWGAIETDKEYYTVKD-CO2) and product peptide (for standard curve only) (NH2-KGGEEEEY-...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/10/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1 [574-1154](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2 [532-1132](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3 [512-1124](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 12.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2 [580-1182](Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of JAK2-JH1/JH2 domain (532 to 1132 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:Inhibition of JAK1-JH1/JH2 domain (574 to 1154 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 12nMAssay Description:Inhibition of JAK3-JH1/JH2 domain (512 to 1124 residues) (unknown origin) pre-incubated before NH2-KGGEEEEYFELVKK-CO2 substrate addition and measured...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/25/2021
Entry Details Article
PubMed
TargetTyrosine-protein kinase JAK1(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 12.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: 0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
2/2/2022
Entry Details
Go to US Patent